NKA Bio

NKA Bio is a private, pre-revenue biotech focused on revolutionizing trauma resuscitation by targeting the body's lethal response to injury, known as shock. Its lead program, NKA01, is an antibody therapy in preclinical development intended for field use by EMS to 'press pause on death' and extend the golden hour for critically injured patients. Founded on pioneering research from Johns Hopkins, the company has secured non-dilutive grant funding, including a $1.25M Air Force SBIR contract, and is preparing to enter clinical trials within 18 months. NKA Bio aims to address the leading cause of death for young adults by bridging the critical gap between injury and definitive surgical care.

Antibody engineering platform targeting 'shock toxins' for rapid stabilization in acute care; focused on developing low-volume, temperature-stable, field-deployable biologic formulations.

The field of pharmacologic agents for hemorrhagic shock resuscitation is active but has seen many failures. Competitors include developers of blood substitutes, pro-coagulant factors (e.g., recombinant Factor VIIa), and other novel biologics. NKA Bio's differentiation lies in its specific antibody approach and intense focus on pre-hospital, field-deployable formulation from the outset.